real-time news and commentary for investors
Thursday, May 9
More on Sarepta Therapeutics' (SRPT) Q1: Nothing particularly groundbreaking regarding...
More on Sarepta Therapeutics' (SRPT) Q1: Nothing particularly groundbreaking regarding eteplirsen in the PR. The company says it is "encouraged" by its correspondence with the FDA and is "finalizing" its response to requests for further information (I, II). A $6.7M decrease in government contract revenue is blamed for the higher (Y/Y) operating loss. Operating expenses were higher as the company expands its Duchenne muscular dystrophy program. Shares +1.24% premarket.